ABPO Abpro Holdings, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $183,000 | $122,000 | — |
| R&D expense | $989,000 | $2.98M | $4.27M | — |
| SG&A expense | $7.46M | $7.12M | $7.60M | — |
| Operating income | -$8.45M | -$9.92M | -$11.75M | -$2.05M |
| Interest expense | $1.13M | $387,000 | $23,000 | — |
| Pretax income | — | -$7.23M | -$11.71M | $1.71M |
| Income tax | — | — | $1.18M | $823,991 |
| Net income | -$2.89M | -$7.23M | $2.82M | $886,918 |
| EBITDA | -$8.43M | -$9.85M | -$11.47M | — |
| EPS (basic) | -1.30 | -22.31 | -0.61 | — |
| EPS (diluted) | -1.30 | -22.31 | -0.61 | — |
| Weighted avg. shares (diluted) | 2.23M | 780,332 | 19.13M | — |
| Balance sheet | ||||
| Cash & equivalents | $82,000 | $2.99M | $861,000 | $7.46M |
| Receivables | $183,000 | $183,000 | $88,000 | — |
| Current assets | $896,000 | $3.78M | $2.04M | $770,226 |
| PP&E, net | — | $37,000 | $102,000 | — |
| Total assets | $1.06M | $4.66M | $3.35M | $310.56M |
| Current liabilities | $9.35M | $19.61M | $15.74M | $2.14M |
| Total liabilities | $9.35M | $19.61M | $16.19M | $15.29M |
| Shareholders' equity | -$8.83M | -$15.49M | -$88.98M | -$11.18M |
| Shares outstanding | 2.73M | 1.69M | 19.17M | — |
| Cash flow statement | ||||
| Operating cash flow | -$6.01M | -$9.03M | -$7.40M | -$1.18M |
| Capital expenditure | — | — | $48,000 | — |
| Free cash flow | — | — | -$7.45M | — |
| Investing cash flow | — | — | $278.44M | -$305.67M |
| Financing cash flow | $3.07M | $11.16M | $849,000 | $307.25M |
| Depreciation & amortization | $21,000 | $74,000 | $279,000 | — |
| Stock-based compensation | $1.49M | $1.93M | $2.31M | $362,500 |
| Share buybacks | — | — | $276.47M | $0 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.